Some examples of what institutes can do ⏬

In Lausanne, we have campus #daycare , holiday #camps for older kids, #technician support during maternity leave, #independence transition grants, etc etc

Yes, the demand often exceeds the availability, but real efforts are being made..

Had a great time meeting all the colleagues and friends at Gustave Roussy! Thanks for the great day!

May is National Cancer Research Month. George Coukos, MD, PhD, a Fellow of the AACR Academy, is one of the 54,000 AACR members who is Bringing Cancer Research to Life.
#NCRM23 #ResearchSavesLives #AACRFellows George Coukos

Big congratulation to Doug Hanahan who has been elected as a member of the Royal Society. This is a great recognition for his outstanding contribution to cancer research! We are lucky of having him at ISREC@EPFL EPFL Life Sciences

Thanks Ben! We appreciate your endorsement.

Daycare. Daycare. Daycare.

This is the most important thing institutes can do to help #parentscientists (not just mums!) - either on-site, or financial supplements to pay for this big additional expense

If you really care about #genderequity , this is how you can help get there!

Delighted to share our newest work on engineering superior effector T states. A new horizon for T cell therapy. Big thanks to Jesus Corria and all the colleagues at Ludwig.

George Coukos and colleagues show that orthogonal cytokine engineering can reprogram CD8 T cells to escape exhaustion leading to tumor regression. Read it here: rdcu.be/daodw Jesus Corria-Osorio George Coukos

nature.com/articles/s4159…

As we ring out 2022, we wish a very happy holiday season & New Year to all our partners, supporters and followers of the academic #CancerResearch community Université de Lausanne CHUV / Centre hospitalier universitaire vaudois Ludwig Cancer.

Our report, Women in science: Perspectives from Ludwig leaders, profiles eight remarkable women affiliated with Ludwig Cancer Research. We'll be posting their stories individually here over the next several days. The whole report: bit.ly/3EbGZUo #LudwigWomenLeaders

Congrats Sohrab, Dmitry and team. Amazing work.

Just out in Nature News & Views, George Coukos and Denarda Dangaj Laniti consider how data that reveal cellular, molecular and mutational landscape, as ovarian cancer tumours grow and spread, might aid efforts to develop new targeted therapies.

Université de Lausanne @chuv Ludwig Cancer

New #JITC commentary: Patient-reported outcomes in adoptive cell-therapy trials: mind the gap bit.ly/3uFjb77 EleonoraGhisoni Matteo Morotti George Coukos Sara Colomer-Lahiguera Massimo Di Maio

TIL Therapy Entering the Mainstream pubmed.ncbi.nlm.nih.gov/36477036/
Delighted to have contributed this editorial. An important step forward for TIL therapy. Congrats to the NKI and Herlev H teams of John Haanen and Inge-Marie Svane. And a big thanks to Steve Rosenberg and colleagues!

Another great panel discussion at #ESMOImmuno22 / Quezada Lab George Coukos Tullia Bruno, PhD Lan Coffman lab /differences between #ovarian & #fallopian tube #cancers (FT has more #TLS per Dr Coffman)/questions from Rieneke van de Ven & many more/HEV 1 marker u need 2 define TLS

Read also the News & Views article on the study by George Coukos, Yaquelin Ortiz-Miranda and Melita Irving:
PDF: rdcu.be/c06Oa
nature.com/articles/s4155…

A commentary by George Coukos, Yaquelin Ortiz-Miranda and Melita Irving -- on @UTSWNews 𝑩𝒂𝒆𝒍 𝒆𝒕 𝒂𝒍.'s study, both just out Nature Cell Biology.

📃go.nature.com/3uxhxEm

Université de Lausanne CHUV / Centre hospitalier universitaire vaudois Ludwig Cancer

DAY3⃣ #ASCO22
Cancer Discovery OncoAlert 🚨

FINAL5⃣papers presented by Elizabeth McKenna
🚫NO PAY WALL🧱
bit.ly/3NVxUT6

Gustave Roussy Institut Curie Katie Janeway Alberto Bardelli Fernanda G. Herrera Melita Irving Gil Morgan, MD George Coukos Oncology UNIL CHUV Ludwig Cancer CHUV / Centre hospitalier universitaire vaudois

Delighted to share our paper, biorxiv.org/content/10.110… . Huge thanks to George Coukos for the opportunity as well as all our collaborators, Santiago Carmona 🧬 🖥️ 🧑🏾‍🔬. A summary of our main findings:

George Coukos Ludwig Cancer Oncology UNIL CHUV A summary of our main Findings
1-Orthogonal combinatorial T-cell engineering overcomes homeostatic barriers to engraftment, reprograms TILs as well as the tumor microenvironment and mediates solid tumor regression in the absence of preconditioning or systemic cytokine support.